From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights
Open Access
- 24 April 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4005
Abstract
Acute myeloid leukemia (AML) is a devastating disease characterized by extensive inter-patient and intra-patient heterogeneity. Despite the introduction of intensive chemotherapy in the 1970s as the standard treatment, the development of mechanism-based targeted therapies since 2017 has been broadening the therapeutic landscape. However, both chemotherapy and targeted therapies continue to face the challenges of primary and secondary resistance. This review summarizes the mechanisms underlying resistance to chemotherapy and targeted therapies in AML and discusses the opportunities and challenges brought by the transition from chemotherapy to precision medicine.Keywords
Funding Information
- Provincial Natural Science Foundation of Hunan (2023JJ20023, 82200198, 82370177)
- National Natural Science Foundation of China (2023JJ20023, 82200198, 82370177)
This publication has 190 references indexed in Scilit:
- Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaAmerican Journal of Hematology, 2024
- Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AMLMolecular Biology Reports, 2024
- Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid LeukemiaAdvanced Science, 2023
- Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsAmerican Journal of Hematology, 2022
- Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunitiesBlood Reviews, 2021
- Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibitionCancer Immunology, Immunotherapy, 2020
- Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trialAmerican Journal of Hematology, 2018
- The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic PotentialCancer Cell, 2015
- Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor CellsCancer Cell, 2015
- Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemiaAmerican Journal of Hematology, 1998